当前位置: 首页 >> 检索结果
4661. Complementary and Alternative Medicines in the Management of Heart Failure: A Scientific Statement From the American Heart Association.
作者: Sheryl L Chow.;Biykem Bozkurt.;William L Baker.;Barry E Bleske.;Khadijah Breathett.;Gregg C Fonarow.;Barry Greenberg.;Prateeti Khazanie.;Jacinthe Leclerc.;Alanna A Morris.;Nosheen Reza.;Clyde W Yancy.; .
来源: Circulation. 2023年147卷2期e4-e30页
Complementary and alternative medicines (CAM) are commonly used across the world by diverse populations and ethnicities but remain largely unregulated. Although many CAM agents are purported to be efficacious and safe by the public, clinical evidence supporting the use of CAM in heart failure remains limited and controversial. Furthermore, health care professionals rarely inquire or document use of CAM as part of the medical record, and patients infrequently disclose their use without further prompting. The goal of this scientific statement is to summarize published efficacy and safety data for CAM and adjunctive interventional wellness approaches in heart failure. Furthermore, other important considerations such as adverse effects and drug interactions that could influence the safety of patients with heart failure are reviewed and discussed.
4662. BioMatrix Versus Orsiro Stents for Coronary Artery Disease: A Multicenter, Randomized, Open-Label Study.
作者: Chang-Hwan Yoon.;Ju-Seung Kwun.;Young Jin Choi.;Jin Joo Park.;Si-Hyuck Kang.;Sun-Hwa Kim.;Jung-Won Suh.;Tae-Jin Youn.;Myeong-Kon Kim.;Kwang Soo Cha.;Seung-Hwan Lee.;Bum-Kee Hong.;Seung-Woon Rha.;Woong Chol Kang.;Jae-Hwan Lee.;Sang-Hyun Kim.;In-Ho Chae.
来源: Circ Cardiovasc Interv. 2023年16卷1期e012307页
Comparative studies of ultrathin-strut biodegradable polymer sirolimus-eluting stent (BP-SES) have reported promising results and validated its excellent outcomes in terms of safety and efficacy. However, there are limited studies comparing BP drug-eluting stents with struts of different thicknesses. We compared the long-term clinical outcomes of patients treated with an ultrathin-strut BP-SES or a thick-strut biodegradable polymer biolimus-eluting stent (BP-BES).
4663. Implementation of an Electronic Health Records-Based Safe Contrast Limit for Preventing Contrast-Associated Acute Kidney Injury After Percutaneous Coronary Intervention.
作者: Neal Yuan.;Justin Zhang.;Rakan Khaki.;Derek Leong.;Chandrashekhar Bhoopalam.;Steven W Tabak.;Yaron Elad.;Joshua M Pevnick.;Susan Cheng.;Joseph E Ebinger.
来源: Circ Cardiovasc Qual Outcomes. 2023年16卷1期e009235页
Contrast-associated acute kidney injury (CA-AKI) after percutaneous coronary intervention is associated with increased mortality. We assessed the effectiveness of an electronic health records safe contrast limit tool in predicting CA-AKI risk and reducing contrast use and CA-AKI.
4665. Association of Clinical Setting With Sociodemographics and Outcomes Following Endovascular Femoropopliteal Artery Revascularization in the United States.
作者: Aishwarya Raja.;Rishi K Wadhera.;Eunhee Choi.;Siyan Chen.;Changyu Shen.;Jose F Figueroa.;Robert W Yeh.;Eric A Secemsky.
来源: Circ Cardiovasc Qual Outcomes. 2023年16卷1期e009199页
After the Centers for Medicare and Medicaid Services modified reimbursement rates for outpatient peripheral vascular intervention in 2008 with the intent of improving access to care, providers began to increasingly perform peripheral vascular interventions in privately owned office-based clinics. Little is known about the characteristics of patients treated in this setting and their long-term outcomes as compared with those treated in hospital-based centers.
4669. Population-Based Epidemiology of Heart Failure in a Low-Income Country: The Haiti Cardiovascular Disease Cohort.
作者: Justin R Kingery.;Nicholas L Roberts.;Jean Lookens Pierre.;Rodney Sufra.;Eliezer Dade.;Vanessa Rouzier.;Rodolphe Malebranche.;Michel Theard.;Parag Goyal.;Altaf Pirmohamed.;Lily D Yan.;Myung Hee Lee.;Denis Nash.;Miranda Metz.;Robert N Peck.;Monika M Safford.;Daniel Fitzgerald.;Marie M Deschamps.;Jean W Pape.;Margaret McNairy.
来源: Circ Cardiovasc Qual Outcomes. 2023年16卷2期e009093页
Cardiovascular disease disproportionately affects persons living in low- and middle-income countries and heart failure (HF) is thought to be a leading cause. Population-based studies characterizing the epidemiology of HF in these settings are lacking. We describe the age-standardized prevalence, survival, subtypes, risk factors, and 1-year mortality of HF in the population-based Haiti Cardiovascular Disease Cohort.
4670. Clinician and Algorithmic Application of the 2019 and 2022 Society of Cardiovascular Angiography and Intervention Shock Stages in the Critical Care Cardiology Trials Network Registry.
作者: Siddharth M Patel.;David D Berg.;Erin A Bohula.;Vivian M Baird-Zars.;Christopher F Barnett.;Gregory W Barsness.;Sunit-Preet Chaudhry.;Lori B Daniels.;Sean van Diepen.;Shahab Ghafghazi.;Michael J Goldfarb.;Jacob C Jentzer.;Jason N Katz.;Benjamin B Kenigsberg.;Patrick R Lawler.;P Elliott Miller.;Alexander I Papolos.;Jeong-Gun Park.;Brian J Potter.;Rajnish Prasad.;N Sarma V Singam.;Shashank S Sinha.;Michael A Solomon.;Jeffrey J Teuteberg.;David A Morrow.; .
来源: Circ Heart Fail. 2023年16卷1期e009714页
Algorithmic application of the 2019 Society of Cardiovascular Angiography and Intervention (SCAI) shock stages effectively stratifies mortality risk for patients with cardiogenic shock. However, clinician assessment of SCAI staging may differ. Moreover, the implications of the 2022 SCAI criteria update remain incompletely defined.
4671. Safety and Efficacy of Sacubitril/Valsartan in Patients With a Failing Systemic Right Ventricle: A Prospective Single-Center Study.
作者: Flavia Fusco.;Giancarlo Scognamiglio.;Assunta Merola.;Angela Iannuzzi.;Michela Palma.;Nicola Grimaldi.;Berardo Sarubbi.
来源: Circ Heart Fail. 2023年16卷2期e009848页
Sacubitril/valsartan was demonstrated to reduce hospitalization rate and mortality in patients with heart failure with reduced ejection fraction. Data on the effects of sacubitril/valsartan in patients with a systemic right ventricle are still lacking.
4672. Assessing Heuristic Bias During Care for Patients Hospitalized for Heart Failure: Get With The Guidelines-Heart Failure.
作者: Senthil Selvaraj.;Stephen J Greene.;Iyanuoluwa Ayodele.;Brooke Alhanti.;Larry A Allen.;Sabra C Lewsey.;Srinath Adusumalli.;Nosheen Reza.;Adrian F Hernandez.;Clyde W Yancy.;Anupam B Jena.;Gregg C Fonarow.;Deepak L Bhatt.
来源: Circ Heart Fail. 2023年16卷2期e010069页
Heuristic biases are increasingly recognized, and potentially modifiable, contributors to patient care and outcomes. Left digit bias is a cognitive bias where continuous variables are categorized by their left-most digit. The impact of this heuristic bias applied to patient age on quality of care in heart failure has not been explored.
4675. Cannabinoid Receptor 2-Centric Molecular Feedback Loop Drives Necroptosis in Diabetic Heart Injuries.
作者: Pan Gao.;Mengying Cao.;Xueli Jiang.;Xiaolin Wang.;Guoping Zhang.;Xinru Tang.;Chunjie Yang.;Issei Komuro.;Junbo Ge.;Liliang Li.;Yunzeng Zou.
来源: Circulation. 2023年147卷2期158-174页
Diabetic heart dysfunction is a common complication of diabetes. Cell death is a core event that leads to diabetic heart dysfunction. However, the time sequence of cell death pathways and the precise time to intervene of particular cell death type remain largely unknown in the diabetic heart. This study aims to identify the particular cell death type that is responsible for diabetic heart dysfunction and to propose a promising therapeutic strategy by intervening in the cell death pathway.
4676. Distinct Transcriptomic and Proteomic Profile Specifies Patients Who Have Heart Failure With Potential of Myocardial Recovery on Mechanical Unloading and Circulatory Support.
作者: Stavros G Drakos.;Rachit Badolia.;Aman Makaju.;Christos P Kyriakopoulos.;Omar Wever-Pinzon.;Christopher M Tracy.;Anna Bakhtina.;Ryan Bia.;Timothy Parnell.;Iosif Taleb.;Dinesh K A Ramadurai.;Sutip Navankasattusas.;Elizabeth Dranow.;Thomas C Hanff.;Eleni Tseliou.;Thirupura S Shankar.;Joseph Visker.;Rana Hamouche.;Elizabeth L Stauder.;William T Caine.;Rami Alharethi.;Craig H Selzman.;Sarah Franklin.
来源: Circulation. 2023年147卷5期409-424页
Extensive evidence from single-center studies indicates that a subset of patients with chronic advanced heart failure (HF) undergoing left ventricular assist device (LVAD) support show significantly improved heart function and reverse structural remodeling (ie, termed "responders"). Furthermore, we recently published a multicenter prospective study, RESTAGE-HF (Remission from Stage D Heart Failure), demonstrating that LVAD support combined with standard HF medications induced remarkable cardiac structural and functional improvement, leading to high rates of LVAD weaning and excellent long-term outcomes. This intriguing phenomenon provides great translational and clinical promise, although the underlying molecular mechanisms driving this recovery are largely unknown.
4677. Isolated Left Ventricular Apical Hypoplasia: A Very Rare Congenital Anomaly Characterized by Multimodality Imaging and Invasive Testing.
作者: Samuel D Maidman.;William D Salerno.;Dan G Halpern.;Robert Donnino.;Muhamed Saric.
来源: Circ Cardiovasc Imaging. 2023年16卷4期e014789页 4678. NLRP3 Inflammasome Activation Through Heart-Brain Interaction Initiates Cardiac Inflammation and Hypertrophy During Pressure Overload.
作者: Yasutomi Higashikuni.;Wenhao Liu.;Genri Numata.;Kimie Tanaka.;Daiju Fukuda.;Yu Tanaka.;Yoichiro Hirata.;Teruhiko Imamura.;Eiki Takimoto.;Issei Komuro.;Masataka Sata.
来源: Circulation. 2023年147卷4期338-355页
Mechanical stress on the heart, such as high blood pressure, initiates inflammation and causes hypertrophic heart disease. However, the regulatory mechanism of inflammation and its role in the stressed heart remain unclear. IL-1β (interleukin-1β) is a proinflammatory cytokine that causes cardiac hypertrophy and heart failure. Here, we show that neural signals activate the NLRP3 (nucleotide-binding domain, leucine-rich-containing family, pyrin domain-containing 3) inflammasome for IL-1β production to induce adaptive hypertrophy in the stressed heart.
4679. Lipoprotein(a) in Youth and Prediction of Major Cardiovascular Outcomes in Adulthood.
作者: Olli Raitakari.;Noora Kartiosuo.;Katja Pahkala.;Nina Hutri-Kähönen.;Lydia A Bazzano.;Wei Chen.;Elaine M Urbina.;David R Jacobs.;Alan Sinaiko.;Julia Steinberger.;Trudy Burns.;Stephen R Daniels.;Alison Venn.;Jessica G Woo.;Terry Dwyer.;Markus Juonala.;Jorma Viikari.
来源: Circulation. 2023年147卷1期23-31页
Elevated lipoprotein(a) [Lp(a)] is a common risk factor for cardiovascular disease outcomes with unknown mechanisms. We examined its potential role in identifying youths who are at increased risk of developing adult atherosclerotic cardiovascular disease (ASCVD).
4680. Macrophage-Derived 25-Hydroxycholesterol Promotes Vascular Inflammation, Atherogenesis, and Lesion Remodeling.
作者: Alberto Canfrán-Duque.;Noemi Rotllan.;Xinbo Zhang.;Irene Andrés-Blasco.;Bonne M Thompson.;Jonathan Sun.;Nathan L Price.;Marta Fernández-Fuertes.;Joseph W Fowler.;Diego Gómez-Coronado.;William C Sessa.;Chiara Giannarelli.;Robert J Schneider.;George Tellides.;Jeffrey G McDonald.;Carlos Fernández-Hernando.;Yajaira Suárez.
来源: Circulation. 2023年147卷5期388-408页
Cross-talk between sterol metabolism and inflammatory pathways has been demonstrated to significantly affect the development of atherosclerosis. Cholesterol biosynthetic intermediates and derivatives are increasingly recognized as key immune regulators of macrophages in response to innate immune activation and lipid overloading. 25-Hydroxycholesterol (25-HC) is produced as an oxidation product of cholesterol by the enzyme cholesterol 25-hydroxylase (CH25H) and belongs to a family of bioactive cholesterol derivatives produced by cells in response to fluctuating cholesterol levels and immune activation. Despite the major role of 25-HC as a mediator of innate and adaptive immune responses, its contribution during the progression of atherosclerosis remains unclear.
|